Effect of PSEN1 mutations on MAPT methylation in early-onset Alzheimer’s disease

Current Alzheimer Research

Volumn 12, Issue 8, 2015, Pages 745-751

  Coupland, Kirsten G ^a,b   Kim, Woojin S ^a,b   Halliday, Glenda M ^a,b   Hallupp, Marianne ^a   Dobsonstone, Carol ^b   Kwok, John B J ^a,b  

^a NEUROSCIENCE RESEARCH AUSTRALIA   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Alzheimer s disease; DNA methylation; Gene expression; MAPT; Mutation; PSEN1

Indexed keywords

PRESENILIN 1; TAU PROTEIN; MAPT PROTEIN, HUMAN; PSEN1 PROTEIN, HUMAN;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN REGION; BRAIN TISSUE; CEREBELLUM; COHORT ANALYSIS; CONTROLLED STUDY; CPG ISLAND; DISEASE DURATION; DNA METHYLATION; FEMALE; GENE EXPRESSION; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IN VITRO STUDY; MALE; ONSET AGE; PRIORITY JOURNAL; PROMOTER REGION; VISUAL CORTEX; GENE EXPRESSION REGULATION; GENETICS; GENOTYPE; METABOLISM; MIDDLE AGED; MUTATION; PATHOLOGY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; COHORT STUDIES; DNA METHYLATION; FEMALE; GENE EXPRESSION REGULATION; GENOTYPE; HUMANS; MALE; MIDDLE AGED; MUTATION; PRESENILIN-1; PROMOTER REGIONS, GENETIC; TAU PROTEINS;

EID: 84942086725     PISSN: 15672050     EISSN: 18755828     Source Type: Journal    
DOI: 10.2174/1567205012666150710110756     Document Type: Article

References (34)

1. Alonso Vilatela ME, Lopez-Lopez M, Yescas-Gomez P. Genetics of alzheimer's disease. Arch Med Res 43(8): 622-631 (2012).
2. Bird TD. Genetic aspects of alzheimer disease. Genet Med 10(4): 231-239 (2008).
3. Selkoe DJ. Amyloid beta-protein and the genetics of alzheimer's disease. J Biol Chem 271(31): 18295-18298 (1996).
4. Schellenberg GD, Montine TJ. The genetics and neuropathology of alzheimer's disease.Acta Neuropathol 124(3): 305-323 (2012).
5. Bateman RJ, Xiong C, Benzinger TLS, Fagan AM, Goate A, Fox NC, et al. Clinical and biomarker changes in dominantly inherited alzheimer's disease. N Engl J Med 367(9): 795-804 (2012).
6. Lee G, Leugers CJ. Tau and tauopathies. Prog Mol Bio Transl Sci 107: 263-293 (2012).
7. Kwok JBJ, Teber ET, Loy C, Hallupp M, Nicholson G, Mellick GD, et al. Tau haplotypes regulate transcription and are associated with parkinson's disease. Ann Neurol 55(3): 329-334 (2004).
8. Caffrey TM, Joachim C, Wade-Martins R. Haplotype-specific expression of the n-terminal exons 2 and 3 at the human mapt locus. Neurobiol Aging 29(12): 1923-1929 (2008).
9. Maloney B, Lahiri DK. Structural and functional characterization of h2 haplotype mapt promoter: Unique neurospecific domains and a hypoxia-inducible element would enhance rationally targeted tauopathy research for alzheimer's disease. Gene 501(1): 63-78 (2012).
10. Nalls MA, Pankratz N, Lill CM, Do CB, Hernandez DG, Saad M, et al. Large-scale meta-analysis of genome-wide association data identifies six new risk loci for parkinson's disease. Nat Genet 46(9): 989-993 (2014).
11. Hoglinger GU, Melhem NM, Dickson DW, Sleiman PM, Wang LS, Klei L, et al. Identification of common variants influencing risk of the tauopathy progressive supranuclear palsy. Nat Genet 43(7): 699-705 (2011).
12. Allen M, Kachadoorian M, Quicksall Z, Zou F, Chai HS, Younkin C, et al. Association of mapt haplotypes with alzheimer's disease risk and mapt brain gene expression levels. Alzheimer's Res Ther 6(4): 39 (2014).
13. Zou F, Chai HS, Younkin CS, Allen M, Crook J, Pankratz VS, et al. Brain expression genome-wide association study (egwas) identifies human disease-associated variants. PLoS Genet 8(6): e1002707 (2012).
14. Lambert JC, Ibrahim-Verbaas CA, Harold D, Naj AC, Sims R, Bellenguez C, et al. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for alzheimer's disease. Nat Genet 45(12): 1452-1458 (2013).
15. Maloney B, Sambamurti K, Zawia N, Lahiri DK. Applying epigenetics to alzheimer's disease via the latent early-life associated regulation (learn) model. Curr Alzheimer Res 9(5): 589-599 (2012).
16. Rosenbloom KR, Armstrong J, Barber GP, Casper J, Clawson H, Diekhans M, et al. The ucsc genome browser database: 2015 update. Nucleic Acids Res 43 (Database issue): D670-681 (2015).
17. Iwata A, Nagata K, Hatsuta H, Takuma H, Bundo M, Iwamoto K, et al. Altered cpg methylation in sporadic alzheimer's disease is associated with app and mapt dysregulation. Hum Mol Genet 23(3): 648-656 (2014).
18. Pearson RC, Esiri MM, Hiorns RW, Wilcock GK, Powell TP. Anatomical correlates of the distribution of the pathological changes in the neocortex in alzheimer disease. Proc Natl Acad Sci USA 82(13): 4531-4534 (1985).
19. Coupland KG, Mellick GD, Silburn PA, Mather K, Armstrong NJ, Sachdev PS, et al. DNA methylation of the mapt gene in parkinson's disease cohorts and modulation by vitamin e in vitro. Mov Disord 29(13): 1606-1614 (2014).
20. Hong EP, Park JW. Sample size and statistical power calculation in genetic association studies. Genomics Inform 10(2): 117-122 (2012).
21. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative pcr and the 2(-delta delta c(t)) method. Methods 25(4): 402-408 (2001).
22. Penna I, Vella S, Gigoni A, Russo C, Cancedda R, Pagano A. Selection of candidate housekeeping genes for normalization in human postmortem brain samples. Intern J Mol Sci 12(9): 5461-5470 (2011).
23. Kwok JB, Halliday GM, Brooks WS, Dolios G, Laudon H, Murayama O, et al. Presenilin-1 mutation l271v results in altered exon 8 splicing and alzheimer's disease with non-cored plaques and no neuritic dystrophy. J Biol Chem 278(9): 6748-6754 (2003).
24. Uhlen M, Oksvold P, Fagerberg L, Lundberg E, Jonasson K, Forsberg M, et al. Towards a knowledge-based human protein atlas. Nat Biotech 28(12): 1248-1250 (2010).
25. Larner AJ. Presenilin-1 mutations in alzheimer's disease: An update on genotype-phenotype relationships. J Alzheimer's Dis 37(4): 653-659 (2013).
26. Lemere CA, Lopera F, Kosik KS, Lendon CL, Ossa J, Saido TC, et al. The e280a presenilin 1 alzheimer mutation produces increased a beta 42 deposition and severe cerebellar pathology. Nat Med 2(10): 1146-1150 (1996).
27. Sepulveda-Falla D, Barrera-Ocampo A, Hagel C, Korwitz A, Vinueza-Veloz MF, Zhou K, et al. Familial alzheimer's diseaseassociated presenilin-1 alters cerebellar activity and calcium homeostasis. J Clin Investig 124(4): 1552-1567 (2014).
28. Buee L, Delacourte A. Comparative biochemistry of tau in progressive supranuclear palsy, corticobasal degeneration, ftdp-17 and pick's disease. Brain Pathol 9(4): 681-693 (1999).
29. Adams SJ, Crook RJP, Deture M, Randle SJ, Innes AE, Yu XZ, et al. Overexpression of wild-type murine tau results in progressive tauopathy and neurodegeneration. Am J Pathol 175(4): 1598-1609 (2009).
30. Shepherd CE, Gregory GC, Vickers JC, Brooks WS, Kwok JB, Schofield PR, et al. Positional effects of presenilin-1 mutations on tau phosphorylation in cortical plaques. Neurobiol Dis 15(1): 115-119 (2004).
31. Van Gassen G, De Jonghe C, Nishimura M, Yu G, Kuhn S, St. George-Hyslop P, et al. Evidence that the beta-catenin nuclear translocation assay allows for measuring presenilin 1 dysfunction. Mol Med (Cambridge, Mass.) 6(7): 570-580 (2000).
32. Marraffini LA, Sontheimer EJ. Crispr interference: Rna-directed adaptive immunity in bacteria and archaea. Nat Rev Genet 11(3): 181-190 (2010).
33. Vidal R, Sammeta N, Garringer HJ, Sambamurti K, Mirvalle Lamb BT, et al. The psen1-l166p-knock-in mutation leads to amyloid deposition in human wild-type amyloid precursor protein yac transgenic mice. FASEB J 26(7): 2899-2910 (2012).
34. Xia D, Watanabe H, Wu B, Lee SH, Li Y, Tsvetkov E, et al. Presenilin-1 knockin mice reveal loss-of-function mechanism for familial alzheimer's disease. Neuron 85(5): 967-981 (2015).